{
  "docId": "019de075-e109-770f-8f32-3054686041b6",
  "docSlug": "9819f3512e565b918c6cfc8e3688cfb2",
  "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Spyre Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 38,
  "pageCount": 38,
  "prevPage": 37,
  "nextPage": null,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 10,
  "notes": "Includes a footnote regarding a 1-for-25 reverse stock split effective September 8, 2023.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-e109-770f-8f32-3054686041b6/38",
  "deckHref": "/decks/019de075-e109-770f-8f32-3054686041b6",
  "deckJsonHref": "/decks/019de075-e109-770f-8f32-3054686041b6.json",
  "deckAnchorHref": "/decks/019de075-e109-770f-8f32-3054686041b6#slide-38",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.026,
        "y": 0.9
      },
      "kind": "disclaimer",
      "text": "*Note: All figures have been retroactively adjusted to reflect the company's 1-for-25 reverse stock split that will be effective as of 12:01 a.m. Eastern Time on September 8, 2023.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "132bd81e-a0fb-414e-aae7-b375abf46aa4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.4,
        "x": 0.58,
        "y": 0.18
      },
      "kind": "list",
      "text": "Shares of common stock and preferred stock were issued to Spyre Therapeutics Inc. security holders in exchange for all of Spyre’s outstanding equity interests. Shares of preferred stock were issued to Spyre Therapeutics Inc. stockholders and to investors in the $210 million private placement. Each share of preferred stock will automatically convert into 40 shares of common stock upon stockholder approval, subject to certain beneficial ownership restrictions set by each holder. Please refer to the company’s SEC filings for additional information.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "350ac907-d227-4757-a268-be6daf77fd38",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.55,
        "x": 0.026,
        "y": 0.15
      },
      "kind": "table",
      "text": "Shares of common stock outstanding 2.6 million; Pre-funded warrants 1.2 million; Merger consideration Shares of common 0.5 million; Shares of preferred 0.4 million; Preferred conversion ratio 1:40; Total pre-financing common equivalent 18.9 million; Concurrent financing Shares of preferred 0.7 million; Common equivalent 28.9 million; Total capitalization (Common) 47.7 million",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "864ca0bf-f380-4e82-945f-311d24346df3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.23,
        "x": 0.026,
        "y": 0.044
      },
      "kind": "title",
      "text": "Capitalization",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0dfe640c-ebfb-431a-8a57-891f36f2c4d1",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}